遺伝子融合検査の世界市場：技術、適応症、用途、エンドユーザー別-2025～2030年予測

遺伝子融合検査市場は、2023年に4億2,834万米ドルと評価され、2024年には4億8,095万米ドルに達すると予測され、CAGR 12.40%で成長し、2030年には9億7,134万米ドルに達すると予測されています。

遺伝子融合検査は、先進的シークエンシング技術によって遺伝子の変化を特定する精密医療において極めて重要です。遺伝子融合検査は、腫瘍形成や遺伝子異常を引き起こす遺伝子再配列を検出することで、がんやその他の遺伝性疾患の診断や治療計画の策定において極めて重要な役割を果たしています。遺伝子融合検査の必要性は、がんの罹患率の増加や、個人の遺伝子プロファイルに合わせて医療介入を行うことで治療効果を高める標的治療の需要によってもたらされています。遺伝子融合検査は臨床腫瘍学、遺伝子研究、個別化医療に幅広く応用されており、エンドユーザーは病院や診断ラボから学術・研究機関まで多岐にわたります。市場成長は、ゲノム研究への投資の増加、次世代シーケンシング技術の進歩、精密医療治療の受け入れ拡大などの影響を受けています。潜在的なビジネス機会としては、非腫瘍セグメントでの応用拡大、高性能スクリーニングの技術進歩、分子診断検査に対する規制の義務化などが挙げられます。しかし、検査コストの高さ、検査プロトコルの標準化不足、複雑な償還環境などの課題が市場拡大の妨げとなっています。また、技術的な障壁や、結果を解釈するための熟練した専門家の必要性による限界にも直面しています。技術革新を活用し研究を促進するためには、費用対効果が高く使いやすい診断プラットフォーム、データ解釈のための人工知能の統合、技術強化のためのバイオテクノロジー企業との提携に注力することが、事業成長のための有効な道筋となります。市場はダイナミックであり、技術の進歩と規制状況の進化の両方が市場を牽引しています。データ分析とユーザーフレンドリーな検査ソリューションの革新に取り組む企業は、現在の勢いを利用する上で最も有利な立場にあります。医療プロバイダーとの継続的なコラボレーションによるフィードバックと改善も、このセグメントを牽引し、治療における臨床的妥当性と有効性の向上につながる可能性があります。

市場力学：急速に進化する遺伝子融合検査市場の主要市場洞察を公開

遺伝子融合検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のがん有病率の上昇
  • ゲノムと分子生物学的研究の増加
  • バイオマーカー探索のための広範な利用
• 市場抑制要因
  • 高コストと遺伝子融合検査へのアクセス制限
• 市場機会
  • リキッドバイオプシー別の遺伝子融合検査技術の出現
  • 個別化医療と標的治療への傾斜
• 市場課題
  • 厳しい規制と熟練した専門家の不足

ポーターのファイブフォース：遺伝子融合検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：遺伝子融合検査市場における外部からの影響の把握

外部マクロ環境要因は、遺伝子融合検査市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：遺伝子融合検査市場における競合情勢の把握

遺伝子融合検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：遺伝子融合検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、遺伝子融合検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：遺伝子融合検査市場における成功への道筋を描く

遺伝子融合検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんの罹患率が上昇
    • ゲノムと分子生物学研究の増加
    • バイオマーカーの発見に広く利用されている
  • 抑制要因
    • 遺伝子融合検査へのアクセスが高額で制限されている
  • 機会
    • 液体生検別の遺伝子融合検査技術の登場
    • 個別化医療と標的療法への傾向
  • 課題
    • 厳しい規制と熟練した専門家の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 遺伝子融合検査市場：技術別

• イントロダクション
• 蛍光in situハイブリダイゼーション（FISH）
• 免疫組織化学（IHC）
• ナノストリング
• NGSアンプリコン
• 逆転写ポリメラーゼ連鎖反応（RT-PCR）

第7章 遺伝子融合検査市場：適応症別

• イントロダクション
• 血液悪性腫瘍
• 固形腫瘍

第8章 遺伝子融合検査市場：用途別

• イントロダクション
• 疾病診断
• 研究

第9章 遺伝子融合検査市場：エンドユーザー別

• イントロダクション
• 学術研究センター
• 病院と診断ラボ
• 製薬・バイオテクノロジー企業

第10章 南北アメリカの遺伝子融合検査市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の遺伝子融合検査市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの遺伝子融合検査市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amoy Diagnostics Co., Ltd.
• Arima Genomics, Inc.
• Biocare Medical, LLC
• Biocartis NV
• Caris Life Sciences
• Danaher Corporation
• Empire Genomics, Inc.
• F. Hoffmann-La Roche Ltd.
• Guardant Health, Inc.
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics, Inc.
• OncoDNA SA
• Paragon Genomics, Inc.
• QIAGEN N.V.
• Quest Diagnostics Incorporated.
• SOPHiA GENETICS SA
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. GENE FUSION TESTING MARKET RESEARCH PROCESS
• FIGURE 2. GENE FUSION TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENE FUSION TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GENE FUSION TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NANOSTRING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NGS AMPLICON, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR), BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HAEMATOLOGICAL MALIGNACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. CHINA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. INDIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. INDIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. ITALY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. ITALY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. POLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. POLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. QATAR GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. QATAR GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Gene Fusion Testing Market was valued at USD 428.34 million in 2023, expected to reach USD 480.95 million in 2024, and is projected to grow at a CAGR of 12.40%, to USD 971.34 million by 2030.

Gene fusion testing is critical in the precision medicine landscape, identifying genetic alterations through advanced sequencing techniques. It plays a pivotal role in diagnosing and developing treatment plans for cancer and other genetic disorders by detecting gene rearrangements that can drive tumorigenesis or genetic malfunctions. The necessity of gene fusion testing is driven by the increasing incidence of cancer and the demand for targeted therapies, which enhance treatment efficacy by tailoring medical interventions to individual genetic profiles. It is applied extensively in clinical oncology, genetic research, and personalized medicine, with end-users ranging from hospitals and diagnostic laboratories to academic and research institutions. Market growth is influenced by rising investments in genomic research, advancements in next-generation sequencing technologies, and the growing acceptance of precision medicine treatments. Potential opportunities include expanding applications in non-oncology segments, technological advancements in high-throughput screening, and regulatory mandates for molecular diagnostic tests. However, challenges such as high testing costs, a lack of standardization in test protocols, and complex reimbursement environments hinder market expansion. The market faces limitations posed by technological barriers and the necessity for skilled professionals to interpret results. To leverage innovation and foster research, focusing on cost-effective and easy-to-use diagnostic platforms, artificial intelligence integration for data interpretation, and partnerships with biotechnology firms for technique enhancement are viable pathways for business growth. The market is dynamic, driven by both technological advancements and evolving regulatory landscapes. Companies poised to innovate in data analytics and user-friendly testing solutions are best positioned to capitalize on the current momentum. Continuous collaboration with healthcare providers for feedback and improvements could also drive the sector towards achieving greater clinical relevance and efficacy in medical treatments.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Fusion Testing Market

The Gene Fusion Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of cancer worldwide
  • Increasing genomic and molecular biology reserach
  • Extensive use for discovery of biomarkers
• Market Restraints
  • High cost and limited accessibility to gene fusion testing
• Market Opportunities
  • Advent of liquid-biopsy based gene fusion testing technologies
  • Inclination towards personalize medicine and targeted therapies
• Market Challenges
  • Stringent regulations and dearth of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Gene Fusion Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Fusion Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Fusion Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Fusion Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Fusion Testing Market

A detailed market share analysis in the Gene Fusion Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Fusion Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Fusion Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gene Fusion Testing Market

A strategic analysis of the Gene Fusion Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gene Fusion Testing Market, highlighting leading vendors and their innovative profiles. These include Amoy Diagnostics Co., Ltd., Arima Genomics, Inc., Biocare Medical, LLC, Biocartis NV, Caris Life Sciences, Danaher Corporation, Empire Genomics, Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Myriad Genetics, Inc., Natera, Inc., NeoGenomics, Inc., OncoDNA SA, Paragon Genomics, Inc., QIAGEN N.V., Quest Diagnostics Incorporated., SOPHiA GENETICS SA, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Gene Fusion Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technique, market is studied across Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Nanostring, NGS Amplicon, and Reverse Transcription Polymerase Chain Reaction (RT-PCR).
• Based on Indication, market is studied across Haematological Malignacies and Solid Tumors.
• Based on Application, market is studied across Disease Diagnosis and Research.
• Based on End User, market is studied across Academic & Research Centers, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer worldwide
    • 5.1.1.2. Increasing genomic and molecular biology reserach
    • 5.1.1.3. Extensive use for discovery of biomarkers
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and limited accessibility to gene fusion testing
  • 5.1.3. Opportunities
    • 5.1.3.1. Advent of liquid-biopsy based gene fusion testing technologies
    • 5.1.3.2. Inclination towards personalize medicine and targeted therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations and dearth of skilled professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gene Fusion Testing Market, by Technique

• 6.1. Introduction
• 6.2. Fluorescence In Situ Hybridization (FISH)
• 6.3. Immunohistochemistry (IHC)
• 6.4. Nanostring
• 6.5. NGS Amplicon
• 6.6. Reverse Transcription Polymerase Chain Reaction (RT-PCR)

7. Gene Fusion Testing Market, by Indication

• 7.1. Introduction
• 7.2. Haematological Malignacies
• 7.3. Solid Tumors

8. Gene Fusion Testing Market, by Application

• 8.1. Introduction
• 8.2. Disease Diagnosis
• 8.3. Research

9. Gene Fusion Testing Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Centers
• 9.3. Hospitals & Diagnostic Laboratories
• 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Gene Fusion Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Gene Fusion Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Gene Fusion Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amoy Diagnostics Co., Ltd.
• 2. Arima Genomics, Inc.
• 3. Biocare Medical, LLC
• 4. Biocartis NV
• 5. Caris Life Sciences
• 6. Danaher Corporation
• 7. Empire Genomics, Inc.
• 8. F. Hoffmann-La Roche Ltd.
• 9. Guardant Health, Inc.
• 10. Illumina, Inc.
• 11. Integrated DNA Technologies, Inc.
• 12. Myriad Genetics, Inc.
• 13. Natera, Inc.
• 14. NeoGenomics, Inc.
• 15. OncoDNA SA
• 16. Paragon Genomics, Inc.
• 17. QIAGEN N.V.
• 18. Quest Diagnostics Incorporated.
• 19. SOPHiA GENETICS SA
• 20. Thermo Fisher Scientific Inc.